Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy.
Claeys
L G Y
LG
Department of Vascular Surgery, University Hospital Herne, Ruhr-University Bochum, 44625-Herne, Germany.
Berg
W
W
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005263:Femoral Artery / Q000293:injuries*; D006401:Hematologic Agents / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced* / Q000150:complications; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D007431:Intraoperative Complications / Q000628:therapy*; D007511:Ischemia / Q000601:surgery; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D014656:Vascular Surgical Procedures / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D006401:Hematologic Agents; D007140:Immunoglobulin Fab Fragments; D006493:Heparin; D000077284:Abciximab